摘要
目的评价Urotensin-Ⅱ受体拮抗剂对糖尿病视网膜病变(DR)微血管病变的影响。方法制备STZ糖尿病大鼠动物模型,随机分成3组对照组(Sham+Veh,11只)、糖尿病未治疗组(DM+Veh,7只)和Urotensin-Ⅱ受体拮抗剂治疗组(DM+362,20只)。每2周测定一次血糖及体重,饲养6个月后处死。每只大鼠左眼用视网膜胰蛋白酶消化铺片法计算周细胞/内皮细胞比值,右眼用透射电镜测量毛细血管基底膜厚度。结果Urotensin-Ⅱ受体拮抗剂治疗组大鼠平均血糖值明显低于糖尿病未治疗组,而平均体重比糖尿病未治疗组略增加。虽然Urotensin-Ⅱ受体拮抗剂治疗组的内皮细胞/周细胞比值和毛细血管基底膜厚度明显较对照组高(E/P比值对照组1.19±0.01,治疗组1.60±0.01,P<0.01);基底膜厚度对照组(83.36±14.46)nm,治疗组(106.40±18.65)nm(P<0.01),但比糖尿病未治疗组显著性降低(E/P比值未治疗组2.10±0.07);基底膜厚度未治疗组(116.91±17.65)nm(P<0.01)。结论Urotensin-Ⅱ受体拮抗剂能有效抑制DR早期微血管病变。
Objective Urotensin-Ⅱ is a vasoactive peptide with stronger vasoconstrictive effectiveness. It may be involved in the pathogenesis of diabetic retinopathy. This paper was to assess the effects of Urotensin-Ⅱ antagonist on microvascular pathological changes in diabetic retinopathy （DR）. Methods Animal models of DR were induced by injection of streptozocin in rats. Experimental rats were randomly divided into Sham ＋ Veh （normal control, 11 rats）, DM ＋ Veh （diabetic model without treatment, 7 rats） and DM ＋ 362 （diabetic model with Urotensin-Ⅱ antagonist treatment, 20 rats） groups. Mean body weight and blood glucose levels of rats were recorded every 2 weeks during the experiment period and rats were scarified at the end of 6 months. Left eye of each rat was processed for elastase digest to determine retinal endothelial/pericyte cell ratios and the right eye were used for transmission electron microscopy examination to detect basement membrane thickness. Results Blood glucose level was significantly higher in the DM ＋ Veh group and DM ＋ 362 group than the Sham ＋ Veh group 2 weeks after diabetes was induced, and that of DM ＋ 362 group was considerably lower in comparison with DM ＋ Veh group after 4 weeks. There was no apparent difference in mean body weight between DM ＋ Veh group and DM ＋ 362 group （P 〉 0.05）. Endothelial cell/pericyte ratios and basement membrane thickness were significantly increased in the DM ＋ 362 rats compared with Sham ＋ Veh rats （1.60±0.01 versus 1.19±0.01 in E/P ratios, P 〈 0.01 and 106.40±18.65 nm versus 83.36±14.46 nm in basement membrane thickness, P 〈 0.01） and significantly reduced in comparison with DM ＋ Veh rats （2.10±0.07 in E/P ratios, P 〈 0.01 and 116.91±17.65 nm in basement membrane thickness, P 〈 0.01）. Conclusion Urotensin-Ⅱ antagonist may be useful in prevention from the early pathological changes of DR.
出处
《眼科研究》
CSCD
北大核心
2006年第2期160-164,共5页
Chinese Ophthalmic Research
